Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.

Marcin Wnuk Leszek DrabikMonika MaronaJoanna SzaleniecAmira BryllPaulina KarczJustyna KolasinskaMonika KolasinskaMaciej ZiekiewiczJacek SkladzienTadeusz PopielaAgnieszka Slowik

Published in: Ear, nose, & throat journal (2020)

Olfactory dysfunction is nearly twice as common in RRMS as in controls and correlates with fatigue level in patients treated with dimethyl fumarate or fingolimod.

Keyphrases

multiple sclerosis
white matter
oxidative stress
sleep quality
systemic lupus erythematosus
depressive symptoms
disease activity